MicroRNA-130B promotes tumor development and is associated with poor prognosis in colorectal Cancer

Neoplasia (United States)

Volumn 15, Issue 10, 2013, Pages 1218-1231

  Colangelo, Tommaso ^a   Fucci, Alessandra ^a   Votino, Carolina ^a   Sabatino, Lina ^a   Pancione, Massimo ^a   Laudanna, Carmelo ^a   Binaschi, Monica ^b   Bigioni, Mario ^b   Alberto Maggi, Carlo ^b   Parente, Domenico ^c   Forte, Nicola ^c   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

^b Menarini Ricerche SpA   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; KI 67 ANTIGEN; MICRORNA; MICRORNA 130B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 84887028386     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13998     Document Type: Article

References (48)

1. Schoen RE, Pinsky P, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bre- salier R, Andriole GL, Buys SS, Crawford ED, et al. (2012). Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366, 2345-2357.
2. Dean M (1998). Cancer as a complex developmental disorder nineteenth Cornelius P. Rhoads Memorial Award Lecture. Cancer Res 58, 5633-5636.
3. Stefani G and Slack FJ (2008). Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9, 219-230.
4. Garzon R, Calin GA, and Croce CM (2009). MicroRNAs in cancer. Annu Rev Med 60, 167-179.
5. Lehrke M, Pascual G, Glass CK, and Lazar MA (2005). Gaining weight: the Keystone Symposium on PPAR and LXR. Genes Dev 19, 1737-1742.
6. Michalik L, Desvergne B, and Wahli W (2004). Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4, 61-70.
7. Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, and Spiegelman BM (2005). Hic-5 regulates an epithelial program mediated by PPARy. Genes Dev 19, 362-375.
8. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, and Spiegelman BM (1998). Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1, 465-470.
9. Pancione M, Sabatino L, Fucci A, Carafa V, Nebbioso A, Forte N, Febbraro A, Parente D, Ambrosino C, Normanno N, et al. (2010). Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 5, e14229.
10. Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli M, et al. (2012). UHRF1 coordinates peroxi- some proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene 31, 5061-5072.
11. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, et al. (2009). Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136, 1242-1250.
12. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, and Colantuoni V (2009). Reduced β-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40, 714-725.
13. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S, Martindale JL, Hutchison ER, Kim HH, Marasa BS, et al. (2011). miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor γ expres-sion. Mol Cell Biol 31, 626-638.
14. Baltimore D, Boldin MP, O'Connell RM, Rao DS, and Taganov KD (2008). MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9, 839-845.
15. Saito K, Kondo E, and Matsushita M (2011). MicroRNA 130 family regulates the hypoxia response signal through the P-body protein DDX6. Nucleic Acids Res 39, 6086-6099.
16. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et al. (2010). MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 46, 1456-1463.
17. Kim BH, Hong SW, Kim A, Choi SH, and Yoon SO (2012). Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol 107, 505-510.
18. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al. (2012). Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7, e35661.
19. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT, Gao C, and Luk Jm (2012). Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2, e000825.
20. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, and Sakuragi N (2013). Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32, 3286-3295.
21. Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X, and Wan XP (2013). miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol 30, 484.
22. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G, Dani C, Amri EZ, and Scheideler M (2009). MicroRNA miR-27b impairs human adipocyte differentiation and targets PPARγ. Biochem Biophys Res Commun 390, 247-251.
23. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, et al. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 10, 1555-1577.
24. Plowman J, Dykes DJ, Melinda H, Simpson-Hellen L, and Alley MC (1997). Human tumor xenograft models in NCI drug development. In Anticancer Drug Development Guide. BA Teicher (Ed). Humana Press, Totowa, NJ. pp. 101-126.
25. Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Sugihara K, Doki Y, et al. (2012). Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res 18, 3054-3070.
26. Irizarry RA, Ooi SL, Wu Z, and Boeke JD (2003). Use of mixture models in a microarray-based screening procedure for detecting differentially represented yeast mutants. Stat Appl Genet Mol Biol 2, Article 1.
27. Tabas-Madrid D, Nogales-Cadenas R, and Pascual-Montano A (2012). Gene Codis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res 40, W478-W483.
28. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, et al. (2012). miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 10, 504-515.
29. Zhang J, Xiao Z, Lai D, Sun J, He C, Chu Z, Ye H, Chen S, and Wang J (2012). miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer 107, 352-359.
30. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gümüs ZH, and Lipkin SM (2012). miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2, 540-553.
31. Holt PR, Moss SF, Kapetanakis AM, Petrotos A, and Wang S (1997). Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? Cancer Epidemiol Biomarkers Prev 6, 131-135.
32. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, and Weinberg RA (2008). Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68, 3645-3654.
33. Stoops SL, Pearson AS, Weaver C, Waterson AG, Days E, Farmer C, Brady S, Weaver CD, Beauchamp RD, and Lindsley CW (2011). Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem Biol 6, 452-465.
34. Tol J and Punt CJ (2010). Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32, 437-453.
35. Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, Kuo CH, Juo SH, and Wang JY (2012). Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 107, 148-154.
36. Nieto MA (2011). The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27, 347-376.
37. Sipos F and Galamb O (2012). Epithelial-to-mesenchymal and mesenchymal to-epithelial transitions in the colon. World J Gastroenterol 18, 601-608.
38. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, et al. (2010). A microRNA targeting dicer for metastasis control. Cell 141, 1195-1207.
39. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, and Esteller M (2012). Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062-2074.
40. Han S, Sidell N, Fisher PB, and Roman J (2004). Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 10, 1911-1919.
41. Teresi RE and Waite KA (2008). PPARgamma, PTEN, and the fight against cancer. PPAR Res 2008, 932632.
42. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Iborra F, et al. (2006). Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26, 7561-7574.
43. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, and Nemenoff RA (2010). Peroxisome proliferator-activated receptor-γ inhibits transformed growth of non-small cell lung cancer cells through selective sup- pression of Snail. Neoplasia 12, 224-234.
44. Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJM, Langers AMJ, Verspaget HW, Hommes DW, Offerhaus GJA, van den Brink GR, and Hardwic JCH (2010). The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31, 1567-1575.
45. Fan XJ, Wan XB, Yang ZL, Fu XH, Huang Y, Chen DK, Song SX, Liu Q, Xiao HY, Wang L, et al. (2012). Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Hum Pathol 44, 173-180.
46. Panigrahy D, Huang S, Kieran MW, and Kaipainen A (2005). PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4, 687-693.
47. Kim KY, Ahn JH, and Cheon HG (2011). Anti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregu- lation and VEGFR-2 downregulation. Mol Cell Biochem 358, 375-385.
48. Rodriguez S and Huynh-Do U (2012). The role of PTEN in tumor angiogenesis. J Oncol 2012, 141236.